Conclusions-Detailed information on the study methodology of the CINRG DMD-NHS lays the groundwork for future analyses of prospective longitudinal natural history data. These data will assist investigators in designing clinical trials of novel therapeutics. Keywords adolescent; adult; child/preschool; follow-up study; health status; human; locomotion; male; muscle strength/physiology; muscular dystrophies/classification; muscular dystrophies/Duchenne/ physiopathology; muscular dystrophies/therapy; phenotype; quality of life/psychology; respiratory function test Tremendous advances over the past 3 decades have improved knowledge of disease pathogenesis caused by dystrophin deficiency. Nonetheless, effective treatments for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) remain limited. Improvements in disease management in DMD, including treatment with glucocorticoid (GC) medications, surgical management of spine deformity, non-invasive ventilation, and more effective treatment of cardiomyopathy, have improved function and survival. This is reflected in a changed natural history of the disease (Fig. 1 ). [1] [2] [3] [4] [5] Despite these advances, patients with DMD continue to lose ambulation in adolescence, frequently require ventilatory support prior to adulthood, develop significant cardiomyopathy in the second to third decade, and have early death in their late teens and into the third and fourth decades of life. [2] [3] [4] [5] [6] Pharmaceutical companies and academic groups have become increasingly interested and involved in DMD-directed therapeutics. These approaches include antisense oligonucleotide (AON)-mediated exon skipping, gene transfer therapy, stem cell delivery, and several smallmolecule administration approaches (e.g., compounds that induce read-through of premature stop codon mutations, promotion of muscle growth by myostatin inhibition, upregulation of utrophin, and GC analogs with improved side-effect profiles). 7 Although not curative, these therapeutic approaches offer hope to significantly alter disease progression and improve quality of life.
The effectiveness of these novel agents will need to be assessed against a background of GC administration. Standards of care for DMD have evolved to incorporate GC use, which is supported by both basic and clinical research studies over the last 20 years. 3 , 4, 8, 9 Recent population-based studies in the USA have shown that >50% of patients with DMD are treated with GC therapy. 10 This change in clinical management has slowed the progression of DMD during the first 2 decades, prompting a reexamination its natural history.
Previous studies have provided a valuable foundation for our current understanding of the natural history, genetic variation, physiological impairments, functional decline, and associated secondary impairments in DMD. 1, [11] [12] [13] [14] [15] [16] However, these natural history studies were limited in their scope of domains, addressed a restricted spectrum of disease severity, and employed shorter durations of follow-up. One of the current fundamental barriers in both the evaluation of DMD-care standards and the optimal design of DMD clinical trials is the lack of contemporary natural history data with clinical trial endpoints obtained across a broad age range and disease-severity spectrum. The varied rate of progression of DMD also necessitates prospective, longitudinal study of a diverse cohort of patients.
To address this gap, the Cooperative International Neuromuscular Research Group (CINRG) has launched the Duchenne Muscular Dystrophy Natural History Study (DMD-NHS) at 20 centers around the world, collecting the most comprehensive and largest, prospective, longitudinal natural history data to date on a cohort of DMD patients. This CINRG DMD-NHS study was designed using the World Health Organization International Classification of Functioning, Disability, and Health (ICF) 17 framework, which includes consideration of body structure and function, individual activities and participation, and environmental factors that impact the overall physical and mental health of the individual in a societal context. We use retrospective-prospective case-cohort study designs in individuals with confirmed Duchenne muscular dystrophy to evaluate the effectiveness of both long-term administration of GC and preventive interventions. These were identified by the CDC DMD Care Considerations Group 3 as requiring further study. Specifically, we aimed to: (1) study the relationship between impairment, activity limitation, participation, and quality of life across a wide age range and spectrum of DMD disease severity using common clinical endpoints employed in clinical trials and novel outcome measures; (2) study the natural history of changes in measures of impairment, activity limitation, and quality of life over periods of 12 months to >5 years of follow-up; (3) examine the associations between both disease characteristics and the use of interventions and the onset of life-altering clinical milestones that are due to the progression of disease; and (4) assess the incidence of secondary conditions of DMD and the relative risks of developing these conditions based on exposure to standard treatment (e.g., glucocorticoids) and preventive interventions recommended by the CDC Care Considerations. 3, 4 The DMD-NHS protocol follows an assessment schedule that models frequent early timepoints and long-term follow-up common to clinical trials, and therefore the data will help inform the design of future clinical trials in DMD. These data will also help identify clinically meaningful endpoints, define changes in endpoints that predict occurrence of clinically meaningful milestones, and help determine minimally clinically important differences.
Here we provide detailed information on our study methodology and lay the groundwork for future analyses of its prospective, longitudinal, natural history data.
METHODS

Participants
Inclusion Criteria-We sought initially to enroll between 10 and 15 participants per year who were between 2 and 28 years years of age. All participants were required to have a clinical picture consistent with typical DMD. Participating caregivers were parents or legal guardians of DMD-NHS participants. Participants between the ages of 2 and <5 years were required to have a diagnosis of DMD confirmed by at least 1 of the following or have an older male sibling who met at least 1 of the following criteria: (1) dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency; (2) positive gene deletion test (missing 1 or more exons) in the central rod domain (exons 25-60) of dystrophin, where the open reading frame (ORF) could be predicted as "out-offrame"; or (3) complete dystrophin gene sequencing showing an alteration (nonsense point mutation, insertion, deletion, duplication, etc.) that was expected to shift the ORF and preclude production of the dystrophin protein. Affected subjects aged ≥5 years and <29 years were required to meet the aforementioned criteria or have documented clinical symptoms referable to DMD (progressive proximal weakness evident by 5 years of age, characteristic gait, positive Gower sign, calf pseudohypertrophy), and direct support of the diagnosis by either (1a) a positive DNA analysis for dystrophin mutation, (2a) a muscle biopsy demonstrating abnormal dystrophin, or (3a) an elevated creatine kinase (CK) level (>5-fold the upper limit of normal), and X-linked pedigree and an affected family member who met either criteria (1a) or (2a) as just described.
Exclusion Criteria-Individuals with DMD were excluded from the study if they were: (1) GC-naive and could ambulate without assistance beyond the 13th birthday; or (2) on GC therapy and could ambulate without assistance beyond the 16th birthday. However, once patients were considered eligible and were enrolled (e.g., 12 years and younger, GC-naive and ambulating) they remained enrolled, regardless of later ambulation status. Our decision to initially exclude patients who continued to ambulate independently beyond the age of 16 years while on GC therapy and beyond 13 years if GC-naive was based on 3 published observations. First, our previous DMD natural history study of GC-naive patients showed the average age at full-time wheelchair transition to be 10 years, with a range of 7-13 years. 13 Second, GC therapy prolonged ambulation by 2-3 years in longer term studies. 8, 9 Third, prior to the application of modern diagnostic testing, clinical criteria held that ambulation past the age of 16 years was consistent with a BMD diagnosis. 18 History of Enrollment-The initial study cohort of 340 patients was recruited from 2009 to 2012. To increase the pool of young DMD participants and to study the impact of GC therapy initiation, beginning in 2012 we began enrolling 100 additional DMD patients between the ages 4 and 8 years of age, using the same criteria as for the initial cohort.
Study Logistics and Support
The study was designed by the study's principal investigator (C.M.M.) and the study chairs at the UC Davis Medical Center (E.K.H. and R.T.A.) and the Children's National Medical Center (A.C.), with early assistance from D.M.E. at Kennedy Krieger Institute. The organizational structure for CINRG is provided in Appendix 1. The CINRG Coordinating Center, located at the Children's National Medical Center, provides operational, data management, and statistical support for the study, as described previously. 19, 20 Clinical evaluators (CEs) participate in annual central training and reliability testing. [19] [20] [21] Two fulltime expert CE trainers are available to train new CEs. Standardized equipment is used at all study sites. The excellent reliability for clinical assessments among the CINRG clinical evaluators has been reported previously and continues to be maintained in the annual testing and when training new CEs who join the network. 21 The CE trainers also receive training on new methods. When they are certified, they train other CINRG CEs, and the new method is added to the network portfolio. Quality control of the data is achieved by the data management team. A comprehensive series of edit-check programs are run against the data sets on an ongoing basis. Sites are queried for any unclear, missing, or inconsistent results of any measure. Sites then respond to queries and correct the data as appropriate. In addition, the Coordinating Center conducts monitoring visits at all sites to ensure data integrity.
Participant-completed assessment tools were translated into languages spoken at the study sites by certified translators and were back-translated into English for verification prior to use.
Protocol Approvals
The institutional or ethics review boards at each participating institution approved the study protocol and the consent/assent documents. Informed consent/assent was obtained from each participant or caregiver as appropriate prior to conducting the study procedures.
Schedule of Assessments
After central review of diagnostic testing results, participants had assessments at baseline and months 3, 6, 9, and 12 (ambulatory), or months 6 and 12 (non-ambulatory), which were timed to approximate the visit frequency commonly employed in DMD clinical trials. One site employed an alternate-visit schedule consistent with local care standards. Long-term follow-up visits were at months 18, 24, and annually thereafter, and are ongoing. Study teams collected age-appropriate measures of functional ability, health status, anthropometrics, timed motor performance, range of motion, skeletal muscle strength, pulmonary function, cardiac function, and health-related quality of life. DNA samples from peripheral blood, buccal swabs, or saliva samples were centrally banked for genotype/ phenotype analysis.
Adaptive Nature of Study Design and Protocol Revisions
We utilized an adaptive study design to permit evolution of the protocol in response to ongoing determination of the feasibility, usefulness, and applicability of promising novel clinical endpoints in DMD. Some patient-reported outcomes (PROs) were discontinued during the course of the study, because it was considered that sufficient prospective natural history data had been obtained. A major modification to the study protocol occurred in 2012, 6 years after initiation of data collection. Original and added measures categorized by the ICF framework are shown in Table 1 , along with time of administration. Details concerning descriptions of the outcome measures and chronology of application of the measures are presented in Appendix 2.
Health Status Assessment
We performed a detailed physical examination and health status history interview at each visit based on DMD-care guidelines 3, 4, [76] [77] [78] and expert opinions from clinicians and researchers with expertise in the care of patients with DMD. Data collected include participant demographics, molecular diagnostics history, family history of DMD, and a complete medical history.
Patients or their parent or primary caregiver completed a survey derived from the National Initiative for Families with Duchenne (NIFD) 79 questionnaire to provide information regarding medical histories beginning with the diagnostic process and including neurological, neuromuscular, neurodevelopmental, respiratory, cardiac, dermatological, nutritional, gastrointestinal, and genitourinary issues. Patients and their caregivers provided information about health-care providers they consulted, use of assistive devices, and school support. English-speaking patients and caregivers in the USA also completed the full NIFD health economics and service utilization questionnaire.
Echocardiograms were not required study evaluations, but measures of left ventricular ejection fraction (LVEF) and shortening fraction (SF) were abstracted from the participant's medical chart for any echocardiogram performed within 1 year prior to the baseline visit and within 1 year of the annual study visits.
Glucocorticoid History
Historical and current use of GC therapy was documented at the time of each visit in addition to all medications and supplements used. As the steroid regimen was not specified in this study (thus leading to considerable variation), it was necessary to create 3 exposure groups to allow summary of grouped data of sufficient size. Participants were grouped as either: (1) GC-naive (not treated with GC ever, or treated for <1 month total and not currently receiving GC); (2) current GC treatment; or (3) past GC treatment for ≥1 month, but not currently receiving GC therapy).
Anthropometrics Assessment
We measured weight and ulnar length (in centimeters) in all patients. For patients who could stand without major truncal deviations we also measured standing height. For all patients (ambulatory and non-ambulatory) we also estimated height using a prediction equation based on ulnar length.
Functional Assessments Using Standardized Scales
Vignos Lower Extremity Functional Grade and Brooke Upper Extremity Grade -Subjects were classified by clinical evaluators according to the Vignos Lower Extremity Functional Grade and the Brooke Upper Extremity Functional Grade. Beginning in 2012, we added the use of lifting weights (200 g, 500 g, and 1000 g), for subjects who score a 1 or 2 on the Brooke Upper Extremity Grade to decrease ceiling effects seen in the more ambulatory subjects.
North Star Ambulatory Assessment-The North Star Ambulatory Assessment (NSAA) is a clinicianrated 17-item functional scale designed for ambulant boys with DMD who are able to stand. [33] [34] [35] [36] [37] Although the NSAA was not available when the CINRG DMD-NHS was initiated, it was since validated in other studies and is in use in international clinical trials. [33] [34] [35] [36] [37] [80] [81] [82] The NSAA was added to the study protocol in 2012.
Egen Klassifikation Scale-The Egen Klassifikation Version 2 (EK2) scale was administered to non-ambulatory subjects beginning in 2012. The EK2 scale was developed and validated as a reliable clinical tool to assess functional ability in non-ambulatory patients with DMD. 38, 39 Additional Functional Tests with Timed Dimension Timed Function Tests-Clinical evaluators obtained timed function measures, including time to rise from the floor (supine to stand), time to climb 4 steps, and time to run/walk 10 meters, in ambulatory subjects who could perform the tests. 1, 11, 26 The primary variables from these tests are the velocities in which the tests were performed.
6-Minute Walk Test-We added the DMD-specific modification of the 6-minute walk test (6MWT) based on our experience in validating the measure 40, 41 and the subsequent widespread utilization of the measure as a primary endpoint or primary efficacy endpoint in DMD multicenter clinical trials. 15, 34, [80] [81] [82] [83] [84] [85] The primary variable derived from the 6MWT is the 6-minute walk distance (6MWD, in meters). To account for maturational influences we have described the use of age-and height-based percent predicted values for 6MWD. 42 The 6MWT has been chosen by the National Institute of Health (NIH) Toolbox project (www.nihtoolbox.org) as a global measure of ambulatory function and endurance.
9-Hole Peg Test-In 2012, we added the 9-Hole Peg Test (9-HPT). The 9-HPT is a reliable, valid, portable, and rapidly administered test used to measure upper limb function and dexterity. 43 The 9-HPT is sensitive to change in adults with neuromuscular and musculoskeletal disorders, 44, 45 and adult and pediatric norms are available. 46 It has been chosen by the NIH Toolbox project as a measure of dexterity, because it is a viable tool for longitudinal epidemiological studies and intervention trials.
Passive Range of Motion Assessment-Passive range of motion (PROM) assesses the extensibility of muscles, tendons, and ligaments through an available ROM. We obtained PROM for knee extension, ankle dorsiflexion, elbow extension, and wrist extension measured to the nearest 5° using standardized goniometry techniques. 11, 26, 86 
Skeletal Muscle Strength Assessment
Manual muscle testing: We performed manual muscle testing (MMT) 1, 11, 19, 26, 87, 88 to measure strength in all participants who could follow 1-step directions and who were strong enough to perform a 1-person assisted stand-pivot transfer to the examination table, as in the previous natural history studies. Attempts to conduct this assessment began at 4 years of age. If the subject was unable to cooperate, the test was skipped and reintroduced at the next visit. Initially, 34 muscle groups were assessed bilaterally. 1, 11, 26 Due to the symmetric nature of the disease and data that showed a high degree of correlation of bilateral measures, the protocol was modified in 2012 so that MMT assessments in ambulant participants were performed unilaterally on the subject's dominant-hand side for 18 muscles (including neck flexors). For non-ambulant participants, we will continue to perform bilateral assessments.
Quantitative muscle testing (QMT):
We measured isometric strength of elbow flexors and extensors and knee flexors and extensors using the CINRG Quantitative Measurement System (CQMS). [19] [20] [21] Hand-grip measurements were also obtained using the CINRG CQMS system in all participants, regardless of mobility status.
Quantitative tip pinch and key pinch strength: Tip pinch and key pinch strength were added as quantitative measures of distal strength in 2012. Tip pinch grip, which measures thenar strength, is an important functional test to evaluate progression of strength loss and function in older non-ambulatory boys and men with DMD. Thenar strength is required to pick up objects, perform fine motor tasks required for operating a power chair joystick, writing, or holding eating utensils. Key pinch (precision grip) is also frequently used in activities of daily living to manipulate and pick up objects.
Pulmonary Function Assessment
We measured forced vital capacity (FVC), forced expiratory volume in 1 second (FEV 1 ), peak expiratory flow rate (PEFR), peak cough flow, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP). Pulmonary function tests were not performed in children <6 years of age who were developmentally appropriate and in some participants <7 years of age who were not developmentally able to cooperate with the testing.
Patient-Reported Outcomes (Health-Related Quality of Life Assessment)
We measured a battery of PROs (Table 1) assessing health-related quality of life (HRQOL) for study participants and their parents or primary caregiver. Study participants completed age-appropriate measures, including the Pediatric Quality of Life Questionnaire (PedsQL), [47] [48] [49] [50] [51] [52] [53] the Pediatric Orthopedic Society of North America Pediatric Musculoskeletal Functional Health Questionnaire (POSNA), [55] [56] [57] [58] [59] the Life Satisfaction Index (LSI), 70 the World Health Organization (WHO) QoL-Bref, [71] [72] [73] the Medical Outcome Study 36-item Short-Form Health Survey (SF-36), 74 and the modified Pittsburgh Sleep Quality Index (PSQI). 75 Caregivers completed age-appropriate proxy measures for the perceived HRQOL of their child using the PedsQL, POSNA, and PSQI measures. Caregivers completed a self-report concerning their own well-being using the PSQI, the SF-36, and the WHO QoL-Bref. In 2012, the PedsQL Neuromuscular Module (NMM) 60, 61 and adult and pediatric NeuroQOL [62] [63] [64] [65] [66] [67] [68] [69] were added to the protocol. Four measures (LSI, PSQI, SF-36, and WHO QOL-Bref) were discontinued after a minimum of 3 years of serial data collection, because sufficient longitudinal data had been collected.
RESULTS
Population Characteristics
Between May 2006 and July 2009, we enrolled 340 individuals with DMD, aged 2-28 years, and their primary caregiver(s) at 20 participating study centers (Table 2) . Median site enrollment included 14 participants (3-49 participants per site). At baseline, 210 of 340 (62%) participants were receiving GC therapy, 48 of 340 (14%) were past GC users, and 82 of 340 (24%) were GC-naive. At baseline, 194 of 340 (57%) participants were ambulatory. The number of participants enrolled by age and their GC use is shown in Figure 2 .
There were a total of 141 participants with DMD who were ≥6 years of age and ambulatory at baseline (an age criterion typically utilized in clinical trials). Among these 141 subjects, there were 23 (16%) who lost ambulation over the first 12 months of the study. For these 23 patients, the age at which ambulation was lost ranged from 7.25 to 17.17 years (mean 10.8 years). From 2006 to 2011, 18 of the 340 DMD patients enrolled in the natural history study died (5%) with the age range of death being 9.9-29.5 years. The oldest patient currently in the study is 32.95 years of age.
DISCUSSION
DMD-NHS Aims Will Address Priorities for DMD Longitudinal Research and More Detailed Characterization of Clinical Trial Outcome Measures across all Stages of DMD
The CINRG DMD-NHS is one of the largest and most comprehensive DMD natural history studies to date and will provide a revised natural history in the era of glucocorticoid therapy. Our first aim is to study the relationship between measures of impairment, activity limitation, participation, and quality of life across a wide age range and spectrum of DMD disease severity using common clinical endpoints employed in clinical trials as well as novel outcome measures. This will provide evidence for the clinical meaningfulness of endpoints by associating changes in endpoints with patient-reported outcomes. The second aim (study the natural history of changes in measures of impairment, activity limitation, and quality of life over periods of 12 months to >5 years of follow-up) will provide prospective data collected in a similar manner to therapeutic trials to inform clinical trial design, inclusion criteria, and sample size calculations. The third aim (examine the associations between both disease characteristics and the use of interventions and the onset of life-altering clinical milestones that are due to the progression of disease) will help define clinically meaningful, functional milestones associated with progression of disease. The fourth aim (assess the incidence of secondary conditions of DMD and the relative risks of developing those conditions based on exposure to standard treatments, such as glucocorticoids, and preventive interventions recommended by the CDC Care Considerations 3,4 ) will provide data that can be used to develop, evaluate, and improve clinical practice guidelines.
Longitudinal DMD research and more detailed characterization of clinical trial outcome measures across all stages of DMD were identified as a high priority by the NIH and U.S. Centers for Disease Control and Prevention and by the European Union TREAT-NMD collaboration. The NIH-led Muscular Dystrophy Coordinating Committee (MDCC) called for additional research to assess the prevalence and natural history of secondary conditions in muscular dystrophy using existing longitudinal study efforts, and to assess the effectiveness of clinical management approaches to prevent and treat secondary conditions using clinically meaningful outcomes. 89 
Conceptual Framework and Comparison of DMD-NHS with other Natural History Studies
The first aim of the DMD-NHS is to study the relationship between measures of impairment, activity limitation, participation, and quality of life across a wide age range and spectrum of DMD disease severity. This aim utilizes a conceptual framework grounded in the biopsychosocial conceptual model of health, function, and quality of life using the World Health Organization International Classification of Functioning, Disability, and Health (ICF). 17 The ICF model includes 4 major domains consisting of body structures, body functions, activities and participation, and environmental factors. It acknowledges reciprocal interactions between domains from the individual genetic and cell function level on up through and including interaction of the individual with his or her environment over time. Body structure items assessed in our study include musculoskeletal, cardiovascular, respiratory, and skin and integumentary systems. Body function items include musculoskeletal movement-related and cardiovascular functions, such as strength, pulmonary function testing, timed motor performance, upper and lower extremity function, and functional activities of daily living, pain, fatigue, and sleep. Activity and participation items include basic topics such as mobility and transfers, ambulatory ability, sports and exercise participation, emotional health, social health, communication, life satisfaction, depression, anxiety, and stigma. Environmental factors assessed in our study are somewhat limited but include items such as family demographics and resources, education and health services utilization, life events, and home and community-built environment. Appendix 3 summarizes the diverse outcome measures that have been used in other natural history studies of persons with DMD organized according this modified ICF framework. Our choice of clinical endpoints and a broad array of PRO measures allow a unique opportunity to develop evidence as to the clinical meaningfulness of endpoints by associating changes in endpoints with PROs.
Significance for Biotechnology and Drug Development: Natural History Data for Novel, Responsive, and Clinically Meaningful Endpoints
Tremendous advances have occurred since the discovery of the dystrophin gene and characterization of the dystrophin protein. [90] [91] [92] [93] Although promising therapeutic targets have emerged for muscular dystrophies, significant barriers to the development of clinical trials remain. 94, 95 Federally mandated NIH scientific advisory committees and expert panels assembled by consumer organizations have identified crucial deficiencies in the design and conduct of translational clinical trials. These include lack of a detailed understanding of the characteristics and natural history of specific neuromuscular diseases, lack of objective clinical outcome measures that are sensitive to changes in disease course, and lack of data that link changes in clinical outcome measures to patient-perceived well-being. [94] [95] [96] In August 2005, the NIH-led MDCC identified research priorities for muscular dystrophies that included: (1) natural history studies; (2) determination of the sensitivity of clinical endpoints to changes in disease severity; (3) determination of the magnitude of changes in endpoints that are clinically meaningful to patients; (4) study of the interrelationship of clinical endpoints for specific muscular dystrophies; (5) development of standardized data collection tools and minimum study data sets; and (6) identification and development of standardized instruments to measure quality of life. 89 Our first 3 study aims address these important needs for therapeutic trials.
Consumers, clinical researchers, the FDA, and industry have increasingly recognized the importance of PRO measures in the determination of clinically meaningful outcomes and validation of endpoints that can be used in therapeutic trials. 97, 98 Regulatory requirements mandate that registration studies incorporate primary endpoints for the measurement of objective, clinically meaningful, "life-changing" events with significant impact on health and well-being. In addition, the FDA has recommended inclusion of PRO measures as an endpoint in clinical trials. 97 The CINRG DMD-NHS includes a broad array of PROs across the lifespan that encompass both patient self-perceived and caregiver/ proxy-perceived health and well-being. The sensitivity of these measures to treatment effects in patients with DMD remains to be determined.
Prior Natural History Studies in DMD Were Conducted Prior to Widespread Use of Glucocorticoids, and There Is a Need for Greater Focus across the Spectrum of Disease
The first large, multicenter study of DMD natural history by the Clinical Investigation in Duchenne Dystrophy (CIDD) group in the 1980s was undertaken prior to the discovery of the dystrophin gene. This DMD cohort comprised 283 boys from early childhood to the early twenties (average age 3.5 years at enrollment). Strength and function were measured longitudinally for up to 10 years. From this data, MMT sample size calculations could be performed and natural history control methods were developed for clinical trials. 1, 11, 12, 87, 88 With that foundation, the group conducted the first comprehensive series of multicenter clinical trials in DMD, establishing the modified MRC MMT as the standard method of strength evaluation for DMD clinical trials and influencing the design of nearly every DMD clinical trial conducted since that time.
Simultaneously, between 1982 and 1992, investigators from the University of California Davis [including the principal investigator (PI) of this study] prospectively followed a cohort of 162 boys and young adults with DMD in a comprehensive single-center observational study. The study PI and colleagues produced a profile of DMD that provided data on anthropometrics, goniometry, strength, cardiac, and respiratory function consistent with the CIDD reports and further added comparisons with healthy age-matched controls using quantitative isometric and isokinetic strength testing, measures of intelligence, school achievement, psychosocial adjustment, and neuropsychological performance. The study also provided data on young adults into their mid-twenties and showed that overall MMT score and individual muscle component scores declined at differing slopes that depended on muscle group tested and participant age. This highlighted the concept that some measures in DMD might be more or less appropriate for short-term clinical trials at specific ages or stages of disease.
The CIDD group demonstrated efficacy of prednisone with a series of clinical trials beginning in 1987. [99] [100] [101] [102] [103] [104] [105] Over the next 15 years, GC therapy gradually became the standard of care for boys with DMD, with a profound effect on disease course. Despite those findings, and American Academy of Neurology Practice Parameters, 8 Cochrane Reviews, 9 and CDC-sponsored care considerations, 3,4 which provide strong recommendations concerning the early administration of GC, the utilization of GC therapy has not been universal due to concerns regarding side effects. 10 
Need to Focus on Natural History of Individuals with DMD Who Are Non-Ambulatory
Few studies of GC use in DMD have focused on non-ambulatory or older patients or clinical endpoints, such as pulmonary function, [105] [106] [107] [108] upper limb function, 107, 108 and spine deformity. [107] [108] [109] [110] Our study presents a unique opportunity to evaluate the long-term impact of years or even decades of GC use and to evaluate clinical effectiveness of GC vis à vis varying durations of exposure and the impact of discontinuing GC therapy in a nonambulatory population. In addition, many of the broad multidisciplinary CDC care considerations, such as pulmonary or cardiac care, focus on management strategies important to the population of individuals with DMD who have transitioned to the wheelchair or who are approaching and entering adulthood. The DMD-NHS will provide data that can be used to plan trials for these individuals and develop, evaluate, and improve clinical practice guidelines across the spectrum of disease.
Limitations of the Study
Inherent Imprecision in Diagnosis and Prediction of Phenotype-The focus of the CINRG DMD-NHS is on patients with dystrophin deficiency clinically diagnosed as DMD. Therefore, the study does not include the entire spectrum of dystrophinopathy. We attempted to include patients who would typically be included in clinical trials of DMD. There is an inherent limitation that patients destined to have milder disease progression might be included in the study, but this is a common limitation of any clinical trial in ambulatory DMD. Despite our best efforts to include a relatively homogeneous population with regard to disease severity, it is possible that we enrolled younger patients who will show milder progression regardless of their GC therapy status. This limitation is inherent in the current imprecision of the prediction of clinical course in dystrophinopathy patients.
The DMD-NHS study is similar in many regards to challenges inherent in all DMD clinical trials that enroll younger ambulatory patients. Most clinical trials in dystrophinopathy have historically targeted patients on the more severe end of the spectrum and labeled by clinicians as "DMD." However, enrollment of young dystrophinopathy patients results in inclusion of patients with milder severity who may improve due to growth and maturational changes or who continue for long periods in a stable "plateau" phase. This presents a challenge when powering a trial to demonstrate a treatment effect. Our study cohort represents a wide spectrum of disease severity and will inform future studies to include design aspects such as stratification by disease severity (even within anbulatory patients) to have different progression expectations for different strata. For example, a study group may expect a novel therapeutic to decrease the rate of decline in older patients, and to increase strength in younger patients. We also have continued to retain patients even if they continue to ambulate past accepted clinical ranges for DMD. Post hoc exclusion of such patients would not be acceptable to the FDA in the context of a prospective, randomized, doubleblind clinical trial.
Biases Created by Clinical Evaluation Protocols-Some of our decisions regarding safe, appropriate, and feasible use of outcome measures truncated our data ranges to specific age-or function-related groups despite the fact that some individuals may have been able to produce measurable results. For instance, our initial decision to limit manual and quantitative strength testing (except for hand grip) to boys who were able to safely complete a 1-person assisted stand-pivot transfer creates a floor effect for those measures beyond which we could have possibly gathered more data. To address this issue we changed the protocol to define that all testing follows standardized positioning in sitting, supine, and prone positions based on muscle strength. Thus, for participants who are unable to perform MMT in the standardized supine positions due to muscle weakness and transfer safety, MMT is now assessed in an alternative sitting position.
Our decision to not enroll patients who were ambulating past age 16 years while on glucococorticoids could conceivably eliminate a small percentage of outlier or intermediate DMD patients who at study initiation ambulate beyond 16 years of age. However, in reality, most ambulatory DMD trials actually enroll very small numbers of such patients in an effort to avoid enrolling Becker muscular dystrophy patients who do not decline much over 12 months. As a case in point, only 2 of 174 patients enrolled in the PTC Therapeutics Ataluren Trial, which focused on severe dystrophinopathy (including both Duchenne and Becker muscular dystrophy), were ambulatory at study entry at beyond 16 years of age. 83 Thus, our inclusion criteria, although perhaps not inclusive of every outlier patient on GC who may have stable function near adulthood, is nonetheless consistent with the typical criteria employed in most ambulatory DMD trials.
Racial/Ethnic and Geographic Composition of Study Cohort-It is common, even
in the case of multinational observational studies, to accrue a study cohort whose racial and ethnic profile is not completely reflective of the overall affected population. Here we established a network with a high degree of geographic variability to enroll participants who closely mirror the populations surrounding participating centers. Despite inclusion of centers on nearly all continents, we still lack an appreciable population of individuals of African descent. Reasons for this remain unclear, but may include environmental factors, such as lack of access to clinics; social factors, such as lower willingness to participate in clinical research; or biological factors, such as true differences in disease prevalence rates.
This study represents the first large natural history study in DMD since GC treatment has become accepted as standard therapy by most clinicians. The study is prospective, geographically varied, and comprehensive, using data from both well-validated and newer measures of strength, function, and HRQOL. Careful documentation of all aspects of the disease process at different ages and stages of severity is essential to the design and interpretation of future therapeutic trials. Future descriptions of this cohort will provide data on the magnitude of change and variability of strength and function over time that will facilitate informed study design features and sample size calculations for trials in different ages and functional groups (including subgroups among ambulatory and non-ambulatory subjects). Our longitudinal data will also provide expanded information on risks and benefits associated with GC treatment and critical information about associations between body structure and body function impairments, activity limitations, medical outcomes, clinically meaningful events or milestones, and PROs such as HRQOL that will inform design of future intervention studies and evaluation of clinical practice guidelines. Changing the natural history of DMD and the application of novel clinical endpoints in 2012. Dx, age at diagnosis; 6MWT, 6-minute walk test. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Distribution of glucocorticoid treatment by age groups and ambulatory status at study entry.
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